Analyst Andrew Fein from H.C. Wainwright maintained a Buy rating on Neurocrine (NBIX – Research Report) and keeping the price target at $185.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Andrew Fein’s rating is based on the promising potential of Neurocrine’s product, Crenessity, in addressing the complex therapeutic needs of patients with Congenital Adrenal Hyperplasia (CAH). The report highlights the insights from a key opinion leader in pediatric endocrinology, who emphasized the advantages of Crenessity in reducing androgen levels without increasing glucocorticoid (GC) doses, thereby allowing for more physiologic GC dosing. This capability is particularly beneficial for women and adults who often face challenges with current treatment regimens.
Furthermore, the report points out the significant market potential for Crenessity, with an estimated 15,000 eligible patients in the US alone. The importance of educating prescribers and ensuring ease of access is also underscored, as these factors are crucial for a successful product launch. The potential for enhanced compliance due to simpler dosing regimens offers an additional incentive for physicians to adopt Crenessity widely. Thus, these factors collectively contribute to Fein’s positive outlook and Buy rating for Neurocrine’s stock.
Fein covers the Healthcare sector, focusing on stocks such as Neurocrine, Palvella Therapeutics, and Vertex Pharmaceuticals. According to TipRanks, Fein has an average return of 4.6% and a 42.19% success rate on recommended stocks.
In another report released on February 13, Wells Fargo also maintained a Buy rating on the stock with a $180.00 price target.